No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
GRI GRI Bio
- 0.315
- -0.003-0.94%
Close May 28 16:00 ET
- 0.330
- +0.015+4.79%
Post 19:13 ET
1.19MMarket Cap-78P/E (TTM)
0.330High0.301Low365.34KVolume0.330Open0.318Pre Close116.71KTurnover10.60%Turnover RatioLossP/E (Static)3.77MShares47.95052wk High0.43P/B1.09MFloat Cap0.28852wk Low--Dividend TTM3.45MShs Float2175.600Historical High--Div YieldTTM9.21%Amplitude0.288Historical Low0.319Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
GRI Bio (NASDAQ: GRI) Participates in Virtual Investor CEO Connect
FRENCHTOWN, NJ / ACCESSWIRE / May 23, 2024 / JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today announced that Marc Hertz, PhD, Chief Executive Officer of
GRI Bio (NASDAQ: GRI) Participates in Virtual Investor "What This Means" Segment Highlighting Positive Preclinical Data From Idiopathic Pulmonary Fibrosis (IPF) and Systemic Lupus Erythematosus (SLE) Programs
Data recently presented at the 2024 American Thoracic Society International Conference and the 14th International Congress on AutoimmunityCompany reiterates 2024 as year of data Click here to watch th
Express News | GRI Bio Inc - Company Targeting Ind Filing for GRI-0803 in Q3 2024 With Topline Data Expected Q4 2024
Express News | GRI Bio Presents Positive Preclinical Data From Pipeline of Nkt Cell Modulators in Development for the Treatment of Systemic Lupus Erythematosus (Sle)
GRI Bio Presents Positive Preclinical Data From Pipeline of NKT Cell Modulators in Development for the Treatment of Systemic Lupus Erythematosus (SLE)
Data presented at the 14th International Congress on AutoimmunityEncouraging preclinical data observed to date on par with OFEV (nintedanib), a leading tyrosine kinase inhibitor with 2025 projected sa
GRI Bio Presents Positive Preclinical Data Demonstrating Lead Program GRI-0621 Reduces the Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF)
Compared to controls, mice treated with GRI-0621 showed improved fibrosis and immunopathology; Inhibition of type 1 invariant Natural Killer T (iNKT) cell activity led to a decrease in fibrosis score
Comments
$GRI Bio(GRI.US$ any hope?
$GRI Bio(GRI.US$
NEWS
GRI Bio (NASDAQ: GRI) Participates in Virtual Investor “What This Means” Segment Highlighting Positive Preclinical Data from Idiopathic Pulmonary Fibrosis (IPF) and Systemic Lupus Erythematosus (SLE) Programs
GRI Bio (NASDAQ: GRI) has participated in a Virtual Investor 'What This Means' segment, showcasing positive preclinical data from its Idiopathic Pulmonary Fibrosis (IPF) and Systemic Lupus Erythematosus (SLE) programs. The data was presented at the 2024 American Thora...
NEWS
GRI Bio (NASDAQ: GRI) Participates in Virtual Investor “What This Means” Segment Highlighting Positive Preclinical Data from Idiopathic Pulmonary Fibrosis (IPF) and Systemic Lupus Erythematosus (SLE) Programs
GRI Bio (NASDAQ: GRI) has participated in a Virtual Investor 'What This Means' segment, showcasing positive preclinical data from its Idiopathic Pulmonary Fibrosis (IPF) and Systemic Lupus Erythematosus (SLE) programs. The data was presented at the 2024 American Thora...
1
GRI Bio Presents Positive Preclinical Data from Pipeline of NKT Cell Modulators in Development for the Treatment of Systemic Lupus Erythematosus (SLE).
GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio,” “we,” “our,” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic, and autoimmune diseases, today announced the presen...
GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio,” “we,” “our,” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic, and autoimmune diseases, today announced the presen...
1
$GRI Bio(GRI.US$ moving back ⬆️
1
3
$GRI Bio(GRI.US$
NEWS
GRI Bio Presents Positive Preclinical Data from Pipeline of NKT Cell Modulators in Development for the Treatment of Systemic Lupus Erythematosus (SLE)
GRI Bio presented promising preclinical data on its NKT cell modulators, GRI-0803 and GRI-0124, at the 14th International Congress on Autoimmunity. The data showed significant potential in treating Systemic Lupus Erythematosus (SLE), with observed inhibition of lupus nephritis and improved survival rates in murine models. GR...
NEWS
GRI Bio Presents Positive Preclinical Data from Pipeline of NKT Cell Modulators in Development for the Treatment of Systemic Lupus Erythematosus (SLE)
GRI Bio presented promising preclinical data on its NKT cell modulators, GRI-0803 and GRI-0124, at the 14th International Congress on Autoimmunity. The data showed significant potential in treating Systemic Lupus Erythematosus (SLE), with observed inhibition of lupus nephritis and improved survival rates in murine models. GR...
1
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg